Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) - Net Assets
Based on the latest financial reports, Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) has net assets worth CN¥1.92 Billion CNY (≈ $281.15 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.13 Billion ≈ $312.10 Million USD) and total liabilities (CN¥211.52 Million ≈ $30.95 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Suzhou Fushilai Pharmaceutical Co. Ltd. to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.92 Billion |
| % of Total Assets | 90.08% |
| Annual Growth Rate | 26.51% |
| 5-Year Change | 203.05% |
| 10-Year Change | N/A |
| Growth Volatility | 59.4 |
Suzhou Fushilai Pharmaceutical Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Suzhou Fushilai Pharmaceutical Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore 301258 asset base for the complete picture of this company's asset base.
Annual Net Assets for Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)
The table below shows the annual net assets of Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024. For live valuation and market cap data, see Suzhou Fushilai Pharmaceutical Co. Ltd. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.89 Billion ≈ $276.11 Million |
-3.02% |
| 2023-12-31 | CN¥1.95 Billion ≈ $284.71 Million |
+3.13% |
| 2022-12-31 | CN¥1.89 Billion ≈ $276.07 Million |
+153.97% |
| 2021-12-31 | CN¥742.84 Million ≈ $108.70 Million |
+19.31% |
| 2020-12-31 | CN¥622.64 Million ≈ $91.11 Million |
+6.99% |
| 2019-12-31 | CN¥581.96 Million ≈ $85.16 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Suzhou Fushilai Pharmaceutical Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 106.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥624.97 Million | 33.12% |
| Other Components | CN¥1.26 Billion | 66.88% |
| Total Equity | CN¥1.89 Billion | 100.00% |
Suzhou Fushilai Pharmaceutical Co. Ltd. Competitors by Market Cap
The table below lists competitors of Suzhou Fushilai Pharmaceutical Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aurora Corp
TW:2373
|
$402.44 Million |
|
Guangdong Provincial Expressway Development Co Ltd
SHE:200429
|
$402.45 Million |
|
Citizens & Northern Corp
NASDAQ:CZNC
|
$402.62 Million |
|
Costamare Bulkers Holdings Limited
NYSE:CMDB
|
$402.68 Million |
|
Enviro Infra Engineers Ltd
NSE:EIEL
|
$402.32 Million |
|
Melcor Developments Ltd.
TO:MRD
|
$402.08 Million |
|
Shenzhen Increase Technology Co Ltd Class A
SHE:300713
|
$402.04 Million |
|
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
|
$401.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Suzhou Fushilai Pharmaceutical Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,945,625,202 to 1,886,913,270, a change of -58,711,932 (-3.0%).
- Net income of 16,406,148 contributed positively to equity growth.
- Dividend payments of 54,976,371 reduced retained earnings.
- Other factors decreased equity by 20,141,709.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥16.41 Million | +0.87% |
| Dividends Paid | CN¥54.98 Million | -2.91% |
| Other Changes | CN¥-20.14 Million | -1.07% |
| Total Change | CN¥- | -3.02% |
Book Value vs Market Value Analysis
This analysis compares Suzhou Fushilai Pharmaceutical Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.54x to 1.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥8.46 | CN¥30.00 | x |
| 2020-12-31 | CN¥9.06 | CN¥30.00 | x |
| 2021-12-31 | CN¥10.80 | CN¥30.00 | x |
| 2022-12-31 | CN¥20.58 | CN¥30.00 | x |
| 2023-12-31 | CN¥21.22 | CN¥30.00 | x |
| 2024-12-31 | CN¥20.58 | CN¥30.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Suzhou Fushilai Pharmaceutical Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.82%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.11x
- Recent ROE (0.87%) is below the historical average (13.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 25.04% | 32.20% | 0.60x | 1.29x | CN¥87.52 Million |
| 2020 | 22.65% | 29.58% | 0.60x | 1.27x | CN¥78.79 Million |
| 2021 | 16.18% | 23.04% | 0.54x | 1.31x | CN¥45.92 Million |
| 2022 | 9.40% | 31.20% | 0.27x | 1.11x | CN¥-11.36 Million |
| 2023 | 5.77% | 22.93% | 0.23x | 1.09x | CN¥-82.38 Million |
| 2024 | 0.87% | 3.82% | 0.21x | 1.11x | CN¥-172.29 Million |
Industry Comparison
This section compares Suzhou Fushilai Pharmaceutical Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,109,695,154
- Average return on equity (ROE) among peers: 0.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) | CN¥1.92 Billion | 25.04% | 0.11x | $402.43 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $108.47 Million | -73.31% | 2.66x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.66 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $-14.51 Million | 0.00% | 0.00x | $443.33 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $660.31 Million | 2.17% | 0.39x | $438.41 Million |
| Chengzhi Shareholding Co Ltd (000990) | $930.16 Million | 5.16% | 0.80x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $3.88 Billion | 15.17% | 0.04x | $3.86 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.19 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $12.48 Billion | 6.70% | 0.16x | $5.40 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $572.48 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.55 Billion | 15.33% | 0.16x | $1.90 Billion |
About Suzhou Fushilai Pharmaceutical Co. Ltd.
Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and … Read more